High Court rules that NICE process lacked transparencyBMJ 2009; 338 doi: http://dx.doi.org/10.1136/bmj.b772 (Published 23 February 2009) Cite this as: BMJ 2009;338:b772
- Clare Dyer
A drug company has won a High Court ruling that the processes of the National Institute for Health and Clinical Excellence (NICE) lack transparency. NICE will have to reconsider its guidelines for treatments to prevent fractures in postmenopausal women with osteoporosis.
Mr Justice Holman said that the advisory body on drug spending in the NHS in England and Wales had merely gone “through the motions so they could claim they had done their duty” in trying to get consent to disclose confidential material to the company and patient groups.
Servier Laboratories, which makes the drug strontium ranelate (Protelos), challenged guidance that it said unfairly restricted access to the treatment for NHS patients.
NICE had refused to disclose the full economic model on which its cost-benefit analysis …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial